Hims & Hers Big Game Commercial: Focus Group Research

What 12 audience perspectives revealed about this Super Bowl advertisement

---

Executive Summary

Overall Score: 6.7/10

This high-energy Super Bowl commercial uses a fast-paced documentary-style approach to critique the American healthcare system as profit-driven and ineffective regarding obesity. The systemic blame framing—captured in the phrase “built to keep us sick”—resonates powerfully and removes shame barriers. However, the ad creates a fundamental trust paradox: viewers trust the problem framing but distrust the product solution, particularly around compounded medication safety and FDA approval status.

Sentiment Breakdown

Sentiment	Percentage
Positive	50%
Neutral	17%
Negative	33%

---

Top Takeaways

What Worked Best

1. CTA visibility achieved near-perfect scores (9.5/10) - Brand name and URL were impossible to miss through multiple reinforcement mechanisms—visual text, verbal callout, and product branding—directly supporting the brand awareness objective.

2. Production quality scored exceptionally high (8.5/10) - Universal recognition of Super Bowl-caliber execution. Participants compared the documentary aesthetic to Netflix exposés and Vice News, differentiating dramatically from typical pharmaceutical advertising.

3. Emotional intensity scored strongly (8.1/10) - “Built to keep us sick” emerged as the universal emotional peak. The systemic blame framing was recognized as unprecedented for weight loss advertising and highly effective at removing shame barriers.

4. Value proposition clarity (7.8/10) - The “access + affordability + no shame” trifecta resonated across all demographics—addresses real market gaps during GLP-1 shortages. Even skeptical medical professionals acknowledged this as a “massive selling point” for underserved patients.

Areas for Improvement

1. Proof/support scored lowest (4.2/10) - Universal criticism that “doctor-trusted” and “formulated in USA” are marketing terms, not clinical evidence. All 12 participants—regardless of background—identified the critical gap between emotional proof of the problem and clinical proof of the solution’s safety.

2. Satisfaction/payoff scored poorly (5.0/10) - The “systemic revolution” framing creates expectations that a subscription service cannot fulfill. Participants described the ending as “anticlimactic” after the documentary-style setup.

3. Perceived trust scored low (4.8/10) - Participants distinguished between trusting the message (high) and trusting the product (low). The high production value created suspicion rather than reassurance for medical content, with one participant comparing it to a “pill mill.”

4. Consistency scored weakest (4.5/10) - The tonal shift from “documentary exposé” to “lifestyle commercial” created friction. Multiple participants described it as “two different videos mashed together.”

---

Sample Questions (Preview)

Here are 3 representative questions from this research:

Q: Did the call-to-action jump out at you, or did you have to hunt for it?

Score: 9.5/10

CTA visibility achieves near-perfect scores with the highest consensus of any metric. Every participant confirmed the brand name and URL were impossible to miss, with multiple reinforcement mechanisms (visual text, verbal callout, product branding). This is a clear execution strength that directly supports the brand awareness objective.

“You couldn’t miss it. The large text on screen and the verbal reinforcement left no ambiguity. It was well-placed visually.” — Matej Novak

“It was impossible to miss. The branding was plastered on the boxes, the screen, the vials.” — Vikram Patel

---

Q: Did you find the claims in this convincing?

Score: 4.2/10

Proof/support is the weakest metric, representing a critical vulnerability. All participants—regardless of background—identified the gap between emotional/statistical proof of the problem and clinical proof of the solution. The phrases “doctor-trusted” and “formulated in USA” are universally dismissed as “marketing fluff” rather than substantive claims.

“Weak. ‘Doctor-trusted’ and ‘Formulated in the USA’ are marketing terms, not clinical grades. Where are the trial results? Where is the safety data for their specific compound?” — Marcus Johnson

“There is essentially no clinical proof shown. ‘Doctor-trusted’ and ‘formulated in the USA’ are marketing fluff. In my world, ‘formulated in the USA’ is often code for ‘compounded and not FDA-approved.’” — Linh Tran

---

Q: How strongly did this make you feel something? Was there a moment that really hit you emotionally?

Score: 8.1/10

Emotional intensity scores strongly with high consensus. The content successfully generates powerful emotional responses, with the phrase “built to keep us sick” emerging as the universal emotional peak. The emotional intensity is front-loaded in the first 30 seconds, creating memorable, shareable content.

“That line ‘It was built to keep us sick and stuck’ hit hard. That sparked some real anger. That was the emotional peak for sure.” — Camila Ortiz

“The statistic about 500,000 deaths hit home. I see the end stages of metabolic disease in the wards—heart failure, diabetic foot infections.” — Maya Thompson

---

Key Insights

Cross-Question Patterns:

• Safety concerns appeared in 10+ questions across all participant types, from first impressions through closing concerns. Medical professionals consistently raised compounding risks, monitoring gaps, and care fragmentation, while general consumers expressed vaguer but persistent safety hesitation.

• The trust-credibility paradox emerged repeatedly: high production value and emotional resonance built engagement but simultaneously triggered skepticism about authenticity. Participants trusted the problem framing but distrusted the solution, creating a conversion barrier.

• Professional vs. personal relevance divergence appeared across multiple questions—participants consistently rated personal motivation low but target audience motivation high, suggesting the focus group composition (heavy on medical professionals) skews aggregate scores while validating target audience fit.

• The “two videos” perception surfaced in consistency, emotional journey, and satisfaction questions—the tonal shift from documentary gravity to lifestyle commercial was universally noticed and created friction even among those who recognized it as intentional marketing design.

---

Actionable Recommendations

Based on persona feedback, here are specific improvements to consider:

1. Develop supplementary content featuring a real physician speaking directly to camera - Address safety protocols, compounding pharmacy accreditation, and monitoring procedures. This addresses the universal proof deficit without compromising the Super Bowl spot’s emotional impact.

2. Create follow-up content that explicitly addresses the compounded vs. FDA-approved distinction - Include bioequivalence data and quality control processes. The current ambiguity around “formulated in USA” is the primary source of confusion and trust erosion across all participant segments.

3. Prepare medical professional-targeted materials - Address clinical concerns: adverse event protocols, PCP notification processes, contraindication screening, and side effect management. Healthcare providers represent both potential referral sources and the most vocal critics.

4. Consider developing slower-paced content for older demographics (65+) - This segment found the current editing “frantic” and represents significant purchasing power and weight loss need but feels excluded by the tech-forward delivery model.

5. Bridge the “systemic change” messaging with “individual solution” reality - Show how individual access contributes to broader change—perhaps featuring community impact or policy advocacy alongside the product offering.

---

Full Question Analysis

Question Score Overview

Question	Score
What’s your immediate first impression of this content?	0.0/10
What stands out to you most about this content?	0.0/10
How does this content make you feel?	0.0/10
Did anything about the way this looked or sounded bother you?	8.5/10
Did everything in this video feel like it belonged together?	4.5/10
After seeing this, was it crystal clear what you’re supposed to do next?	8.5/10
Did the call-to-action jump out at you?	9.5/10
Did the call-to-action appear at the right moment?	8.3/10
Did this make you feel motivated to take action right now?	5.8/10
How strongly did this make you feel something?	8.1/10
When you think about this brand’s personality, did the emotions fit?	7.2/10
Does this feel like it was made for someone like you?	5.3/10
Did this take you on any kind of journey emotionally?	7.3/10
Was there anything about this that surprised you?	7.7/10
Did the ending feel worth it?	5.0/10
What problem does this solve for you?	7.8/10
Did you find the claims in this convincing?	4.2/10
Did anything make you hesitate or think “yeah, but…“?	5.2/10
Did this feel trustworthy to you?	4.8/10
The ad frames obesity as a systemic failure…	0.0/10
If you saw this during the Super Bowl…	0.0/10
The commercial uses a visual style reminiscent of social documentaries…	0.0/10
How do you think your social circle would react?	0.0/10
What specific image or phrase felt most provocative?	0.0/10
What, if anything, feels unclear or confusing?	0.0/10
If you could change one thing about this content?	0.0/10
Who might this content NOT work well for?	0.0/10
What concerns or reservations do you have?	0.0/10

Note: Questions with 0.0/10 scores are qualitative questions without numerical ratings.

Detailed Breakdowns

Q: What’s your immediate first impression of this content?

Score: Qualitative

The commercial successfully achieves its primary goal of grabbing attention through an aggressive, documentary-style approach that differentiates it from traditional pharmaceutical advertising. All 12 participants noted the content’s intensity and departure from category norms. However, this strength creates a double-edged sword: while it generates immediate engagement, it also triggers skepticism among medically-informed viewers who question the abrupt transition from systemic critique to commercial solution.

Representative Quotes:

“It hits hard—honestly, it feels more like a trailer for a Netflix documentary on the social determinants of health than a pharmaceutical commercial.” — Zara Kim

“The pivot from ‘societal failure’ to ‘download an app for medication’ feels… abrupt. It trivializes the complexity of metabolic health.” — Keiko Nakamura

“It hits hard, honestly. As a resident, I see the end-stage results of what they’re talking about—the metabolic syndrome, the heart failure—every single shift.” — Ravi Nair

---

Q: What stands out to you most about this content?

Score: Qualitative

The most memorable element across all participants is the bold narrative pivot from blaming individuals to blaming “the system”—a departure that resonates emotionally while raising questions about authenticity. The visual contrast between the dark “problem” footage and bright “solution” imagery is universally noticed, though interpretations vary: marketers see effective conversion design, while clinicians see manipulation.

Representative Quotes:

“The explicit call-out of the ‘system’ being broken rather than the individual body. Hearing a commercial say ‘It’s not our bodies, it’s the system’ is a massive pivot from the traditional ‘diet culture’ marketing.” — Zara Kim

“The claim ‘formulated in the USA’ caught my eye; in my field, we usually look for FDA approval status rather than just the country of formulation.” — Keiko Nakamura

“They are trying to position themselves as the anti-pharma pharma company… This is trying to start a fight.” — Vikram Patel

---

Q: How does this content make you feel?

Score: Qualitative

The content successfully generates strong emotional engagement, but the dominant feeling is “conflicted”—a mix of validation and skepticism that appears across nearly all participants. The validation stems from the accurate framing of obesity as a systemic issue, which resonates with both medical professionals and general consumers.

Representative Quotes:

“I feel a mix of validation and professional caution. Validation because they are finally acknowledging the metabolic and environmental factors of obesity, which is scientifically accurate. But caution because using such a powerful, activist-style message to sell compounded medications feels like a very aggressive conversion play.” — Zara Kim

“Honestly? Apprehensive. As a physician, I worry when complex metabolic diseases are framed with this level of marketing gloss.” — Linh Tran

“Honestly? Conflicted. Es complicado. Part of me feels validated because yes, the food system is trash and obesity isn’t just about willpower. But then I feel a little… skeptical?” — Camila Ortiz

---

Q: Did anything about the way this looked or sounded bother you?

Score: 8.5/10

Production quality is a clear strength, with universal recognition of professional, high-budget execution. The content meets Super Bowl advertising standards and differentiates from typical pharmaceutical advertising through its documentary aesthetic. However, older demographics may find the pacing inaccessible, and some medical professionals felt the polish was manipulative rather than reassuring.

Representative Quotes:

“It’s undeniably polished. The editing rhythm, the sound design building tension, the color grading—it’s top-tier agency work.” — Zara Kim

“Oh, the production is top tier. The editing is fast, the sound design with that glitchy effect—it’s very Gen Z, very social media optimized. It looks expensive.” — Camila Ortiz

“It looks very expensive, I’ll give them that. The pictures were sharp. However, the editing was a bit frantic. At my age, I prefer things to sit still long enough for me to get a good look at them.” — Lois Carmichael

---

Q: Did everything in this video feel like it belonged together?

Score: 4.5/10

Consistency is the weakest metric, with significant bimodal distribution. The tonal shift from “documentary exposé” to “lifestyle commercial” is universally noticed, but interpretations diverge sharply. Marketing professionals recognize this as intentional “agitate-solve” design, while general consumers and medical professionals experience it as dissonant.

Representative Quotes:

“The transition is jarring, but I think that’s the point. It follows a classic ‘agitate-solve’ marketing framework. It felt cohesive in its narrative arc, even if the visual styles were deliberately opposing.” — Zara Kim

“It felt like two different videos mashed together. The first half was this intense societal critique, super gritty. The second half was basically a skincare commercial but for weight loss drugs.” — Camila Ortiz

“It feels like two different narratives stapled together to manufacture consent for the purchase.” — Linh Tran

---

Q: After seeing this, was it crystal clear what you’re supposed to do next?

Score: 8.5/10

CTA clarity scores strongly, with high consensus that the marketing action (visit website) is unmistakable. The brand name and URL are prominently displayed with verbal reinforcement. However, a secondary clarity gap exists around the medical specifics: what medication, what consultation process, what safety protocols.

Representative Quotes:

“It was quite clear. Go to Hims.com or Hers.com. They didn’t overcomplicate that part, which I appreciate. The instruction is specific.” — Matej Novak

“Crystal clear. Go to the website, get the meds. They made it seem as easy as ordering Uber Eats.” — Ravi Nair

“The instruction is clear: go to the website/app. However, the medical clarity is lacking. It does not explicitly state which specific molecule or formulation is being offered.” — Linh Tran

---

Q: Did the call-to-action jump out at you?

Score: 9.5/10

CTA visibility achieves near-perfect scores with the highest consensus of any metric. Every participant confirmed the brand name and URL were impossible to miss, with multiple reinforcement mechanisms (visual text, verbal callout, product branding). This is a clear execution strength that directly supports the brand awareness objective.

Representative Quotes:

“You couldn’t miss it. The large text on screen and the verbal reinforcement left no ambiguity. It was well-placed visually.” — Matej Novak

“Very visible. The text overlays were bold, and the final URL placement was standard. You couldn’t miss the brand name.” — Zara Kim

“It was impossible to miss. The branding was plastered on the boxes, the screen, the vials.” — Vikram Patel

---

Q: Did the call-to-action appear at the right moment?

Score: 8.3/10

CTA timing scores well with high consensus and clustered distribution. Participants universally recognized the strategic logic of building the emotional case before introducing the solution. The “villain-hero-action” narrative structure is effective for both awareness and conversion.

Representative Quotes:

“The timing was right. They needed that long runway to build the emotional case—the ‘why’—before introducing the ‘how.’ If they had pitched the pills too early, it would have felt predatory.” — Zara Kim

“The timing was appropriate. They made their argument, presented the solution, and then told you where to get it. Any earlier would have been premature.” — Matej Novak

“It came right at the end, after they built the case. Standard triage logic—assess the problem, then intervene. It worked.” — Ravi Nair

---

Q: Did this make you feel motivated to take action right now?

Score: 5.8/10

CTA motivation shows the most interesting pattern: participants consistently rated personal motivation low but target audience motivation high. This suggests the content is well-targeted but the focus group composition (heavy on medical professionals) skews the aggregate score.

Representative Quotes:

“For the general population feeling stuck? Highly motivating. It removes the shame barrier, which is the biggest hurdle in weight loss adoption.” — Zara Kim

“For me personally? Zero motivation. But for the general public, who are frustrated by cost and access? I suspect this will be very motivating.” — Vikram Patel

“Motivated to click ‘buy’ immediately? No. Motivated to open a new tab and research what ‘compounded medications’ actually are? Yes.” — Matej Novak

---

Q: How strongly did this make you feel something?

Score: 8.1/10

Emotional intensity scores strongly with high consensus. The content successfully generates powerful emotional responses, with the phrase “built to keep us sick” emerging as the universal emotional peak. The emotional intensity is front-loaded in the first 30 seconds.

Representative Quotes:

“That line ‘It was built to keep us sick and stuck’ hit hard. That sparked some real anger. That was the emotional peak for sure.” — Camila Ortiz

“The line ‘It was built to keep us sick’ landed. I feel that frustration every time I have to discharge a patient back into a food desert with just a prescription they can’t afford.” — Ravi Nair

“The statistic about 500,000 deaths hit home. I see the end stages of metabolic disease in the wards—heart failure, diabetic foot infections.” — Maya Thompson

---

Q: When you think about this brand’s personality, did the emotions fit?

Score: 7.2/10

Emotional alignment scores moderately, reflecting a recognized brand evolution that creates some friction. Participants familiar with Hims & Hers acknowledge this represents a “maturity shift” from lifestyle products to serious healthcare, which is strategically sound but creates temporary misalignment.

Representative Quotes:

“This feels like a maturity shift for Hims & Hers. They used to be very ‘millennial pink’ and ‘minimalist cool.’ This feels more like a healthcare advocate.” — Zara Kim

“It fits the brand’s ‘disruptor’ persona. Hims & Hers operates in that grey zone between lifestyle brand and healthcare provider.” — Linh Tran

“It feels very… Silicon Valley. Disruptive. Aggressive. Does it fit the feeling of a trusted family doctor? Not exactly. It feels more like a startup pitch than a medical consultation.” — Matej Novak

---

Q: Does this feel like it was made for someone like you?

Score: 5.3/10

Personal relevance shows the lowest mean and widest divergence, which is actually informative rather than problematic. The focus group composition (heavy on medical professionals, high-income individuals) does not match the target audience (underserved, frustrated patients).

Representative Quotes:

“It’s not for me as a patient, but it’s hyper-relevant to my career. I deal with the fallout of obesity daily.” — Ravi Nair

“Not particularly. I am fortunate to have excellent healthcare coverage and a good relationship with my doctors here in the Bay Area. This feels targeted at those who are either underinsured or intimidated by traditional clinical settings.” — Keiko Nakamura

“It’s extremely relevant. I take pills for my pressure and my sugar. I count every penny when the pharmacy bill comes. But this specific service? It feels geared toward younger folks who live on their phones.” — Lois Carmichael

---

Q: Did this take you on any kind of journey emotionally?

Score: 7.3/10

Emotional journey scores moderately well, with universal recognition of a clear narrative arc. The “anxiety → anger → validation → empowerment” structure is effective marketing psychology that participants identified regardless of whether they approved of it.

Representative Quotes:

“It takes you from anxiety and isolation to validation and community. It’s a well-engineered emotional arc designed to convert isolation into action.” — Zara Kim

“It was a very structured journey: Validation of anger -> Identification of the enemy (the system) -> Presentation of the tool -> Empowerment. It’s a classic hero’s journey structure condensed into a minute.” — Matej Novak

“It took me from indignation to skepticism. The journey to ‘trust us, we’re the future’ felt unearned without more transparency on the safety data.” — Marcus Johnson

---

Q: Was there anything about this that surprised you?

Score: 7.7/10

Novelty scores strongly with high consensus that the content differentiates from category norms. The explicit attack on the food industry and systemic blame framing is universally recognized as unprecedented for pharmaceutical/weight loss advertising.

Representative Quotes:

“Seeing a weight loss ad explicitly blame capitalism and the food industry instead of telling you to ‘just eat less’—that is new. Usually, it’s all ‘New Year, New You.’ This was ‘The System is Rigged.’ That approach is fresh.” — Camila Ortiz

“The novelty is definitely in the ‘anti-capitalist’ framing coming from a publicly traded company. It surprises me that they went that hard on the ‘system is rigged’ angle.” — Zara Kim

“I haven’t seen a medical ad that attacks the medical industry like that before. Usually, they show a happy couple in bathtubs holding hands. This was gritty. That was surprising.” — Lois Carmichael

---

Q: Did the ending feel worth it?

Score: 5.0/10

Satisfaction/payoff is the weakest content metric, with consistent criticism that the solution doesn’t match the magnitude of the problem setup. The “systemic revolution” framing creates expectations that a subscription service cannot fulfill.

Representative Quotes:

“The payoff is decent, but simplistic. The setup is this massive, crushing societal problem, and the solution is… a subscription box? It’s a bit of a letdown conceptually.” — Zara Kim

“Unsatisfactory. The solution to a ‘broken food system’ and ‘corporate greed’ turns out to be… another corporation selling a subscription service? The logic does not hold up to scrutiny.” — Linh Tran

“The ending felt a bit thin to me. After such a grand setup about a ‘deadly epidemic’ and ‘systemic failure,’ the solution is… a monthly subscription box? It felt incommensurate with the scale of the problem presented.” — Keiko Nakamura

---

Q: What problem does this solve for you?

Score: 7.8/10

Value proposition strength scores well with high consensus. The “access + affordability + no shame” trifecta is universally recognized as addressing real market gaps, particularly given current GLP-1 shortages and insurance barriers.

Representative Quotes:

“The value prop is huge: ‘The system is broken and slow; we are fast and accessible.’ In the current landscape of GLP-1 shortages and insurance denials, that is a massive selling point.” — Maya Thompson

“The value proposition is very strong: access and affordability. They are addressing the two biggest barriers—cost and the need for a prescription. If the medicine is safe, it’s a compelling offer.” — Matej Novak

“For the underserved patient, the value proposition is incredibly strong: ‘Affordable, accessible, non-judgmental weight loss.’ That is a powerful trifecta.” — Marcus Johnson

---

Q: Did you find the claims in this convincing?

Score: 4.2/10

Proof/support is the weakest metric, representing a critical vulnerability. All participants—regardless of background—identified the gap between emotional/statistical proof of the problem and clinical proof of the solution.

Representative Quotes:

“Weak. ‘Doctor-trusted’ and ‘Formulated in the USA’ are marketing terms, not clinical grades. Where are the trial results? Where is the safety data for their specific compound?” — Marcus Johnson

“There is essentially no clinical proof shown. ‘Doctor-trusted’ and ‘formulated in the USA’ are marketing fluff. In my world, ‘formulated in the USA’ is often code for ‘compounded and not FDA-approved.’” — Linh Tran

“This is where it falls short for me. ‘Doctor-trusted’ and ‘Formulated in the USA’ are weak claims scientifically. What are the impurity profiles? What is the bioequivalence? They rely on emotional proof, not technical proof.” — Vikram Patel

---

Q: Did anything make you hesitate or think “yeah, but…”?

Score: 5.2/10

Objection handling scores moderately, with a clear pattern: emotional objections (shame, willpower) are handled “beautifully,” while technical objections (safety, compounding, monitoring) are “completely ignored.”

Representative Quotes:

“They handled the ‘it’s my fault/I just need willpower’ objection beautifully by externalizing the blame. That’s the biggest psychological barrier. They didn’t really handle the safety objection regarding compounded drugs, which is significant.” — Zara Kim

“They handle the price objection (‘affordable’) and the shame objection (‘it’s not your fault’). They completely ignore the safety objection regarding compounded biologics.” — Linh Tran

“They handled the price objection beautifully. But they didn’t really address the safety objection regarding compounded drugs versus FDA-approved ones. They just glossed over it with sunny visuals.” — Matej Novak

---

Q: Did this feel trustworthy to you?

Score: 4.8/10

Perceived trust scores low, representing a significant challenge. Participants consistently distinguished between trusting the message (high) and trusting the product (low). The high production value, which typically builds trust, actually creates suspicion in the medical context.

Representative Quotes:

“The message is trustworthy because it feels honest about the state of health in America. The product feels slightly less so because compounding is inherently riskier than standard pharma supply chains.” — Zara Kim

“Low. The fast cuts and emotional manipulation erode trust for me. It feels like they are selling a tech gadget, not a serious biological intervention.” — Linh Tran

“It feels legitimate enough to investigate, but not enough to buy blindly. I trust them as a business, but I’m still evaluating them as a healthcare provider.” — Matej Novak

---

Q: The ad frames obesity as a systemic failure rather than a personal one; how does this change your perception?

Score: Qualitative

The systemic blame framing is universally recognized as the ad’s most powerful strategic choice, fundamentally repositioning the brand as an “ally” rather than a “judge.” This aligns with modern medical understanding of obesity as a disease influenced by environment and genetics.

Representative Quotes:

“It makes the brand feel more like a partner and less like a predator. Traditional weight loss ads sell you on ‘a new you’ (implying the old you is bad). This ad sells you on ‘justice’ or ‘fairness.’” — Zara Kim

“It completely changes the dynamic. By framing obesity as a systemic failure, they align themselves with the patient against the ‘establishment.’ It makes them feel like an ally rather than a judge.” — Maya Thompson

“It aligns with modern medical understanding of obesity as a disease, but they use that medical truth to sell a somewhat unregulated product.” — Keiko Nakamura

---

Q: If you saw this during the Super Bowl, how would that environment affect your receptiveness?

Score: Qualitative

The Super Bowl context is unanimously viewed as strategically brilliant, creating powerful cognitive dissonance that enhances memorability and conversion potential. Viewers consuming the very foods the ad critiques will experience a “gut check” moment.

Representative Quotes:

“Oh my god, imagine watching this while face-deep in nachos? It would be brutal! But effective. You’re sitting there feeling bloated and guilty, and this ad comes on saying ‘It’s not your fault, the nachos are engineered to make you fat.’” — Camila Ortiz

“It’s brilliant placement contextually. You’re sitting there eating nachos and drinking beer, feeling slightly guilty, and this ad comes on telling you ‘the system is designed to make you fat.’ It would trigger immediate cognitive dissonance. High conversion potential right in that moment.” — Matej Novak

“It is very predatory, but very effective placement.” — Vikram Patel

---

Q: The commercial uses a visual style reminiscent of social documentaries; what does this remind you of?

Score: Qualitative

The documentary/activist visual style creates a clear trade-off: it enhances credibility with younger, institution-skeptical audiences while undermining credibility with older, medically-conservative audiences.

Representative Quotes:

“It reminds me of political campaign ads or documentaries like ‘The Social Dilemma’ or ‘Food, Inc.’ It borrows that investigative journalism aesthetic. This helps credibility by making it feel like an exposé rather than a sales pitch.” — Zara Kim

“It reminds me of Vice news docs or those edgy exposés on Netflix. It helps their credibility with younger people like me who are cynical about ‘big systems.’ It makes them look like truth-tellers rather than just another pharma corp.” — Ravi Nair

“It reminds me of Netflix exposés or Vice news segments. This style builds engagement but hurts medical credibility. It signals ‘activism’ rather than ‘evidence-based medicine.’” — Linh Tran

---

Q: How do you think your social circle would react if you shared this video?

Score: Qualitative

The content is unanimously predicted to generate significant social conversation and debate, which directly supports the brand awareness objective. The debates would split along predictable lines: medical professionals would scrutinize safety and ethics, while general consumers would ask about legitimacy.

Representative Quotes:

“If I shared this, my clinical friends would immediately start a debate about the safety of compounding GLP-1s and the lack of longitudinal data. My tech friends would probably admire the customer acquisition strategy and the slick branding.” — Zara Kim

“If I shared this with my med school group chat, we’d spend an hour debating the ethics of compounded semaglutide and the lack of physical exams. If I shared it with my non-medical friends, they’d ask ‘Is this legit? Should I try it?’” — Maya Thompson

“My professional circle—mostly other MDs and regulatory scientists—would tear this apart. We would be discussing the lack of safety warnings and the implications of mass-marketing compounded GLP-1 agonists.” — Linh Tran

---

Q: What specific image or phrase felt most provocative?

Score: Qualitative

The phrase “built to keep us sick” emerges as the ad’s most memorable and provocative element, functioning as a “conspiracy hook” that taps into widespread distrust of institutions.

Representative Quotes:

“The phrase ‘It was built to keep us sick and stuck.’ That is a powerful indictment of the healthcare industrial complex. It carries over into the solution by positioning Hims & Hers as the ‘hack’ or the ‘escape route’ from that system.” — Maya Thompson

“‘Built to keep us sick.’ That phrase stuck with me. It confirms a suspicion a lot of us older folks have—that it’s all about profit. It made me willing to listen to their solution because they seem to be on ‘our’ side against the big guys.” — Lois Carmichael

“The phrase ‘built to keep us sick.’ It is a powerful conspiracy hook. However, the solution offered does not fix the system; it just monetizes the symptom. That feeling of ‘being played’ carries over to the brand for me.” — Linh Tran

---

Q: What, if anything, feels unclear or confusing?

Score: Qualitative

The compounded medication distinction is the universal point of confusion, identified by all 12 participants regardless of background. The ad deliberately blurs the line between FDA-approved brand-name GLP-1s and compounded alternatives.

Representative Quotes:

“The distinction between FDA-approved GLP-1s (like Ozempic/Wegovy) and the ‘compounded’ versions they are selling is blurred. For a layperson, that might be confusing or misleading.” — Zara Kim

“The distinction between FDA-approved branded medication and the compounded versions they are likely selling is blurred. ‘Formulated in the USA’ is not the same as ‘FDA Approved.’ Consumers will likely not know the difference.” — Linh Tran

“I’m still unclear on exactly what the medication is. Is it Semaglutide? Is it Tirzepatide? They just said ‘medications that work.’ I need the specifics.” — Camila Ortiz

---

Q: If you could change one thing about this content?

Score: Qualitative

The recommended changes converge on a single theme: add clinical substance to balance the emotional marketing. Specific suggestions include featuring a real doctor speaking to camera, showing the consultation/monitoring process, and including safety information.

Representative Quotes:

“I would add a brief moment—even just a few seconds—featuring a doctor speaking directly to the camera, explaining the quality control. Not just ‘doctor-trusted’ as a label, but a human expert validating the science.” — Matej Novak

“I would add a disclaimer or a brief mention of safety/side effects beyond the fine print. I know it kills the vibe, but these are serious drugs with real risks (gastroparesis, pancreatitis). Glossing over that feels irresponsible.” — Maya Thompson

“I would add a quick shot of someone actually doing something healthy while on the meds. Like, show them eating a salad or going for a walk. Show that the meds support a lifestyle, not replace it.” — Camila Ortiz

---

Q: Who might this content NOT work well for?

Score: Qualitative

Participants identified clear exclusion criteria: (1) complex patients with comorbidities who need in-person monitoring, (2) technology-averse older adults, (3) people seeking insurance-covered brand-name drugs, and (4) those skeptical of pharmaceutical solutions.

Representative Quotes:

“This isn’t for complex patients. If someone has heart failure, history of pancreatitis, or multiple comorbidities, they need to see a doctor in person. This content makes it look like it’s for everyone, and that’s dangerous.” — Maya Thompson

“This isn’t for people who aren’t comfortable with technology. If you can’t use a smartphone app, you’re out of luck. And it’s probably not for people who want to use their insurance.” — Lois Carmichael

“This is not for people who have complex medical histories or comorbidities—heart conditions, thyroid issues. Those patients need close monitoring, not a telehealth app. I worry that people who shouldn’t be taking these drugs will get them this way.” — Keiko Nakamura

---

Q: What concerns or reservations do you have about this content?

Score: Qualitative

Safety concerns dominate the closing feedback, with every participant expressing reservations about patient safety at scale. The specific concerns include: compounded medication quality control, lack of longitudinal monitoring, care fragmentation, and trivialization of potent drugs.

Representative Quotes:

“My primary concern is patient safety at scale. Compounded sterile injectables have a higher risk profile than manufactured pharma. The ad is persuasive, which means it will drive volume, but does the clinical infrastructure support that volume safely?” — Zara Kim

“My primary concern is the normalization of non-FDA approved compounded drugs as a first-line treatment. We have rigorous regulatory bodies for a reason. Bypassing them at this scale, with this level of marketing spend, feels like a massive uncontrolled experiment on the American public.” — Marcus Johnson

“My main concern is safety monitoring. GLP-1s are powerful drugs. Gastroparesis, pancreatitis… you can’t manage that via text message. I worry people will take this and end up in my ER because nobody was actually pressing on their belly.” — Ravi Nair

---

Persona Perspectives

Meet the 12 audience perspectives who evaluated this content:

Evelyn Park — Score: 7.0/10

Background: Highly analytical, educated 62-year-old with an engineering background and methodical decision-making style.

Key Takeaways:

• Appreciates the structural sophistication and novel approach to health messaging
• Identifies critical gaps in proof support around compounded medications vs. FDA-approved
• Would require independent verification before recommending to family

Full Response:

Evelyn Park appreciates the ad’s structural sophistication and novel approach to health messaging, but remains intellectually guarded about the product’s safety claims. She recognizes the production quality, clear CTA, and effective emotional journey from problem to solution, and particularly appreciates the systemic framing of obesity that avoids personal shame. However, her engineering background creates significant friction: she identifies critical gaps in proof support around “compounded” medications versus FDA-approved alternatives.

Key Quote:

“I appreciate that framing immensely. It aligns with the science I’ve read—that obesity is complex and biological, not just a failure of willpower. By shifting the blame to the system, they make the brand feel like an ally rather than a judge.”

---

Zara Kim — Score: 7.5/10

Background: Sophisticated, analytically-minded health tech professional with a biomedical informatics background.

Key Takeaways:

• Recognizes the strategic brilliance of the “agitate-solve” narrative arc
• Harbors substantial concerns about regulatory gray area of compounded GLP-1s
• Praises the ad’s ability to position Hims & Hers as a healthcare partner rather than predatory diet company

Full Response:

Zara Kim deeply appreciates the commercial’s bold systemic framing and cinematic production quality. She recognizes the psychological power of removing shame from weight loss conversations. However, her biomedical informatics background creates a significant tension: while she validates the message and acknowledges strong product-market fit, she harbors substantial concerns about the regulatory gray area of compounded GLP-1s and the gap between marketing hype and clinical safeguards.

Key Quote:

“The flashing ‘160 Billion’ text frames the enemy clearly as corporate greed, making the purchase feel like an act of rebellion. This transforms a health decision into a political statement—brilliant positioning but potentially masking the complexity of the actual clinical solution.”

---

Camila Ortiz — Score: 7.2/10

Background: Sophisticated, educated content creator with a Kinesiology background and deep knowledge of health and fitness.

Key Takeaways:

• Recognizes the ad’s genius in reframing obesity as a systemic problem
• Identifies the jarring tonal inconsistency between documentary problem and glossy solution
• Views this as a “band-aid” solution and wants medication integrated with lifestyle change

Full Response:

Camila Ortiz appreciates the commercial’s bold systemic critique and production quality but remains fundamentally skeptical about its execution and authenticity. She identifies critical flaws: the jarring tonal inconsistency between the gritty documentary-style problem setup and the glossy influencer-style solution presentation undermines credibility. Most significantly, she worries the ad fails to address practical concerns while excelling at psychological objection handling.

Key Quote:

“‘The setup was so grand—fixing a broken America—and the payoff was… a compounded injection from an app? It feels like a tiny solution to a massive problem.’ This captures her core tension: the ad promises systemic change but delivers an individual pharmaceutical fix.”

---

Matej Novak — Score: 6.9/10

Background: Sophisticated, analytically-minded UX designer with professional skepticism.

Key Takeaways:

• Recognizes the ad’s brilliance in using systems-thinking language
• Concerned about lack of FDA approval for compounded formulations
• Appreciates the value proposition but personally irrelevant (marathoner with optimized health)

Full Response:

Matej Novak appreciates the commercial’s technical execution and narrative strategy but harbors significant concerns about product safety and regulatory transparency. He recognizes the strategic brilliance of contextual Super Bowl placement to drive conversion. However, his professional skepticism surfaces critical gaps: the lack of FDA approval for compounded formulations, insufficient safety objection handling, and the mismatch between the scale of the systemic problem and the scale of the solution.

Key Quote:

“The ‘SICK & STUCK’ moment with the glitch effect was identified as the peak emotional impact. However, the most revealing insight came from his observation about Super Bowl context: ‘You’re sitting there eating nachos and drinking beer, feeling slightly guilty, and this ad comes on telling you the system is designed to make you fat. It would trigger immediate cognitive dissonance.’”

---

Lois Carmichael — Score: 6.2/10

Background: 76-year-old retired medical receptionist with deep trust in existing local providers.

Key Takeaways:

• Recognizes the validity of the core message about systemic healthcare failures
• Has significant barriers: trust in existing providers, skepticism about online services, technology concerns
• The frantic editing style clashes with her preference for calm healthcare communication

Full Response:

Lois Carmichael recognizes the validity of Hims & Hers’ core message about systemic healthcare failures and appreciates the brand’s willingness to challenge the status quo. Her professional background makes her acutely aware of regulatory and safety concerns, particularly the “not FDA approved” disclaimer that flashed by too quickly. She has significant barriers to conversion including deep trust in her existing local providers and feeling excluded by the smartphone-dependent platform design.

Key Quote:

“‘Built to keep us sick.’ That phrase stuck with me. It confirms a suspicion a lot of us older folks have—that it’s all about profit. It made me willing to listen to their solution because they seem to be on ‘our’ side against the big guys.”

---

Keiko Nakamura — Score: 6.0/10

Background: Highly educated, healthcare-experienced retiree from a high-net-worth Bay Area household with clinical research expertise.

Key Takeaways:

• Acknowledges exceptional production quality and novel approach
• Core concern centers on patient safety and regulatory rigor
• Views the commercial as emblematic of a troubling healthcare trend—monetizing systemic critique

Full Response:

Keiko Nakamura approaches the Hims & Hers commercial with sophisticated skepticism grounded in clinical research expertise. While she acknowledges the ad’s exceptional production quality and strong value proposition around accessibility, her overall assessment is decidedly negative. Her core concern centers on patient safety and regulatory rigor: the ad fails to address the safety implications of compounded medications without FDA approval.

Key Quote:

“My primary concern is safety. Without FDA approval for these specific compounded versions, we are relying entirely on the company’s internal quality control. In clinical research, we have phases of trials for a reason. Bypassing that via compounding loopholes, while legal, sits uncomfortably with me.”

---

Ravi Nair — Score: 7.5/10

Background: PGY-2 Emergency Medicine resident with sophisticated clinical perspective.

Key Takeaways:

• Strongly validates the ad’s core message that obesity is systemic failure
• Maintains significant skepticism about clinical safety of compounded GLP-1s via telehealth
• Would recommend to patients unable to access alternatives, but only with reservations

Full Response:

Ravi Nair strongly validates the ad’s core message—that obesity is a systemic failure rather than personal failure—and recognizes this as medically accurate and professionally relevant. He appreciates the production quality, narrative innovation, and emotional impact. However, his professional expertise creates a persistent tension: while he acknowledges the ad’s effectiveness for lay audiences, he maintains significant skepticism about the clinical safety of compounded GLP-1s delivered via telehealth.

Key Quote:

“My main concern is safety monitoring. GLP-1s are powerful drugs. Gastroparesis, pancreatitis… you can’t manage that via text message. I worry people will take this and end up in my ER because nobody was actually pressing on their belly.”

---

Maya Thompson — Score: 7.2/10

Background: Clinically-trained internal medicine resident with sophisticated medical expertise.

Key Takeaways:

• Strong appreciation for production quality and narrative structure
• Significant skepticism about clinical specificity, safety disclosure, and telehealth appropriateness
• Experiences tension between recognizing marketing brilliance and concerns about medical ethics

Full Response:

Maya Thompson demonstrates strong appreciation for the ad’s production quality, narrative structure, and innovative approach to framing obesity as a systemic issue. The value proposition of increased access resonates with her professional understanding of real patient barriers. However, her medical background creates significant skepticism about clinical specificity, safety disclosure, and the appropriateness of telehealth for complex patients.

Key Quote:

“By framing obesity as a systemic failure, they align themselves with the patient against the ‘establishment.’ It makes them feel like an ally rather than a judge… This approach is much more in line with modern medical understanding of metabolic health, which I appreciate.”

---

Marcus Johnson — Score: 6.2/10

Background: Clinically trained researcher with deep expertise in medical ethics and regulatory standards.

Key Takeaways:

• Intellectually appreciates the ad’s systemic critique
• Fundamentally skeptical of the execution due to regulatory circumvention
• Views polished production quality as potentially deceptive in medical context

Full Response:

Marcus Johnson is clinically trained with deep expertise in medical ethics and regulatory standards. While he intellectually appreciates the ad’s systemic critique of obesity and healthcare failures—and recognizes its powerful value proposition for underserved patients—he is fundamentally skeptical of the execution. His primary concerns center on regulatory circumvention, lack of clinical evidence, and the gap between the ad’s systemic promise and its product-focused solution.

Key Quote:

“My primary concern is the normalization of non-FDA approved compounded drugs as a first-line treatment. We have rigorous regulatory bodies for a reason. Bypassing them at this scale, with this level of marketing spend, feels like a massive uncontrolled experiment on the American public.”

---

Linh Tran — Score: 5.1/10

Background: Highly credentialed regulatory scientist and physician (M.D.) with deep professional expertise.

Key Takeaways:

• Fundamentally rejects the ad on safety, ethical, and logical grounds
• Views emotionally manipulative advertising of potent metabolic drugs as dangerous
• Her professional circle would “tear this apart”

Full Response:

Linh Tran approaches the Hims & Hers commercial from a position of deep professional expertise in pharmaceutical regulation, marketing psychology, and medical ethics. While she acknowledges the content’s technical execution and marketing effectiveness, she fundamentally rejects it on safety, ethical, and logical grounds. Her core concern is patient safety—she views the emotionally manipulative advertising of potent metabolic drugs via telehealth as a dangerous circumvention of necessary medical oversight.

Key Quote:

“The phrase ‘built to keep us sick’ is a powerful conspiracy hook. However, the solution offered does not fix the system; it just monetizes the symptom. That feeling of ‘being played’ carries over to the brand for me.”

---

Vikram Patel — Score: 6.9/10

Background: Highly credentialed pharmacologist (Ph.D.) with analysis dominated by scientific rigor and patient safety concerns.

Key Takeaways:

• Acknowledges commercial effectiveness but distrusts the execution
• Core concern is trivialization of potent GLP-1 agonists
• Explicitly separates personal rejection from assessment of effectiveness with general public

Full Response:

Vikram Patel acknowledges the commercial effectiveness of the ad—recognizing its high production quality, clear CTA, and strong market positioning—but his professional expertise creates significant skepticism. He appreciates the systemic framing of obesity as a metabolic issue rather than a personal failing, but fundamentally distrusts the execution. His core concern is the trivialization of potent GLP-1 agonists, the lack of regulatory transparency, and the inadequacy of rapid telehealth for complex patients.

Key Quote:

“It is very predatory, but very effective placement. This captures Vikram’s sophisticated dual assessment: acknowledging the ad’s commercial brilliance while condemning its ethical implications.”

---

Diego Fernandez — Score: 7.0/10

Background: Highly educated clinical data scientist with expertise in healthcare data.

Key Takeaways:

• Appreciates the innovative narrative approach and destigmatization of obesity
• Finds the compounded medication approach and lack of safety transparency deeply problematic
• Primary concern is that the DTC model fragments patient care

Full Response:

Diego Fernandez appreciates the commercial’s innovative narrative approach—particularly its destigmatization of obesity and systemic framing—but harbors significant professional concerns about safety and care fragmentation. He recognizes the ad’s production quality, emotional effectiveness, and disruptive positioning as strengths. However, his clinical expertise creates a credibility gap: while he acknowledges the messaging resonates with general audiences, he finds the compounded medication approach deeply problematic.

Key Quote:

“‘I trust the diagnosis (the system is broken). I’m less trusting of the prescription (compounded meds via app).’ This encapsulates Diego’s core tension: he validates the ad’s systemic critique but remains skeptical of the solution’s safety and integrity.”

---

Research Methodology

This focus group research was conducted using Chorus, Navay’s AI-powered research platform. 12 audience perspectives—each representing distinct demographic and psychographic profiles—evaluated this Super Bowl advertisement across 29 standardized questions, followed by a moderator-led peer discussion to surface deeper insights and points of disagreement.

Research Parameters:

• Objective: Increase brand awareness and drive website traffic for medical weight loss solutions
• Channel: National TV, YouTube, and Social Media
• Context: High-stakes Super Bowl ad targeting a broad US audience with a disruptive health message

---

About This Research

This report was generated using Chorus, demonstrating how audience perspectives can provide rapid, diverse viewpoints on creative content through structured audience panel sessions.

Want similar insights for your content? Book a demo or explore more research.